JP2004537974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004537974A5 JP2004537974A5 JP2002571810A JP2002571810A JP2004537974A5 JP 2004537974 A5 JP2004537974 A5 JP 2004537974A5 JP 2002571810 A JP2002571810 A JP 2002571810A JP 2002571810 A JP2002571810 A JP 2002571810A JP 2004537974 A5 JP2004537974 A5 JP 2004537974A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- gag
- hiv env
- pol
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 108700004029 pol Genes Proteins 0.000 claims 16
- 108700004026 gag Genes Proteins 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 101150088264 pol gene Proteins 0.000 claims 12
- 101150098622 gag gene Proteins 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 8
- 241000288906 Primates Species 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 239000013612 plasmid Substances 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 5
- 102100034353 Integrase Human genes 0.000 claims 4
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- 108010078428 env Gene Products Proteins 0.000 claims 2
- 108700004025 env Genes Proteins 0.000 claims 2
- 101150030339 env gene Proteins 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- 108010061833 Integrases Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000037452 priming Effects 0.000 claims 1
- 230000005026 transcription initiation Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27443401P | 2001-03-08 | 2001-03-08 | |
| PCT/US2002/006713 WO2002072754A2 (en) | 2001-03-08 | 2002-03-01 | Mva expressing modified hiv envelope, gag, and pol genes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010019755A Division JP2010115208A (ja) | 2001-03-08 | 2010-01-29 | 改変ＨＩＶエンベロープ、ｇａｇ、およびｐｏｌ遺伝子を発現するＭＶＡ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004537974A JP2004537974A (ja) | 2004-12-24 |
| JP2004537974A5 true JP2004537974A5 (enExample) | 2006-01-05 |
| JP4554887B2 JP4554887B2 (ja) | 2010-09-29 |
Family
ID=23048178
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002571810A Expired - Lifetime JP4554887B2 (ja) | 2001-03-08 | 2002-03-01 | 改変ＨＩＶエンベロープ、ｇａｇ、およびｐｏｌ遺伝子を発現するＭＶＡ |
| JP2010019755A Ceased JP2010115208A (ja) | 2001-03-08 | 2010-01-29 | 改変ＨＩＶエンベロープ、ｇａｇ、およびｐｏｌ遺伝子を発現するＭＶＡ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010019755A Ceased JP2010115208A (ja) | 2001-03-08 | 2010-01-29 | 改変ＨＩＶエンベロープ、ｇａｇ、およびｐｏｌ遺伝子を発現するＭＶＡ |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20040146528A1 (enExample) |
| EP (1) | EP1372710B1 (enExample) |
| JP (2) | JP4554887B2 (enExample) |
| CN (1) | CN100446812C (enExample) |
| AT (1) | ATE445411T1 (enExample) |
| AU (1) | AU2002252199B2 (enExample) |
| CA (1) | CA2454959C (enExample) |
| CY (1) | CY1109659T1 (enExample) |
| DE (1) | DE60234018D1 (enExample) |
| DK (1) | DK1372710T3 (enExample) |
| ES (1) | ES2334335T3 (enExample) |
| PT (1) | PT1372710E (enExample) |
| WO (1) | WO2002072754A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8623379B2 (en) * | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
| CN1311871C (zh) | 2000-03-02 | 2007-04-25 | 爱莫里大学 | Dna表达载体及其应用方法 |
| AU2002252199B2 (en) | 2001-03-08 | 2008-01-03 | Emory University | MVA expressing modified HIV envelope, GAG, and POL genes |
| AU2003220111B2 (en) * | 2002-03-08 | 2008-07-31 | Emory University | Compositions and methods for generating an immune response |
| CN1490056A (zh) * | 2002-10-18 | 2004-04-21 | ��¡���ɵ°��̲��о����� | 针对hiv-1的免疫方法和组合物 |
| EP2359851A3 (en) * | 2003-03-28 | 2011-08-31 | The Government of the United States of America, represented by The Secretary, Department of Health and Human Services | MVA expressing modified hiv envelope, gag, and pol genes |
| EP1675613B1 (en) | 2003-09-15 | 2012-05-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Hiv vaccines based on env of multiple clades of hiv |
| DE602004009743T2 (de) * | 2003-11-24 | 2008-08-28 | Bavarian Nordic A/S | Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara |
| CN1304580C (zh) * | 2004-07-09 | 2007-03-14 | 楼伟 | 重组表达人获得性免疫缺陷病毒I型的表面糖蛋白gp160 |
| AU2005274948B2 (en) | 2004-07-16 | 2011-09-22 | Genvec, Inc. | Vaccines against aids comprising CMV/R-nucleic acid constructs |
| AU2012202786B8 (en) * | 2004-08-27 | 2015-05-21 | Emory University | Recombinant MVA viruses expressing Clade A/G, Clade B, and Clade C modified HIV ENV, GAG and POL genes |
| ES2539010T3 (es) * | 2004-08-27 | 2015-06-25 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Virus MVA recombinantes que expresan genes env, gag y pol modificados de VIH clado A/G, clado B, y clado C |
| ES2281252B1 (es) | 2005-07-27 | 2009-02-16 | Consejo Superior De Investigaciones Cientificas | Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida. |
| FR2893254B1 (fr) * | 2005-11-14 | 2007-12-21 | Biomerieux Sa | Composition comprenant un vecteur synthetique colloidal bioresorbable et un vecteur viral et son utilisation prophylactique, therapeutique et diagnostique. |
| CN101020052A (zh) * | 2006-02-16 | 2007-08-22 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 基于复制型痘苗病毒载体的艾滋病疫苗 |
| WO2007102326A1 (ja) * | 2006-03-07 | 2007-09-13 | Yokohama City University | アデノウイルス５型／３５型ベクターとワクシニアウイルスｍｖａベクターとの併用による強力な免疫誘導 |
| CA2670804A1 (en) * | 2006-05-19 | 2007-11-29 | Sanofi Pasteur Inc. | Immunological composition |
| US20080274992A1 (en) * | 2007-03-26 | 2008-11-06 | Jean-Louis Excler | Recombinant modified ankara viral hiv-1 vaccines |
| EP2042604A1 (en) * | 2007-09-26 | 2009-04-01 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | VV promoter driven overexpression of recombinant antigens |
| US20090263828A1 (en) * | 2008-04-16 | 2009-10-22 | Franco Lori | Novel assay for precursor T-cells having high proliferative capacity (PHPC-asay) |
| WO2010029260A1 (fr) * | 2008-09-10 | 2010-03-18 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Construction d'un gène synthétique codant pour gag de vih1 et son utilisation pour obtention de vaccins anti-vih-1 |
| AP2012006258A0 (en) * | 2009-10-13 | 2012-06-30 | Geovax Inc | Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens. |
| CN102791396B (zh) | 2010-05-19 | 2014-10-29 | 新日铁住金株式会社 | 具有l 字状形状的零件的冲压成型方法 |
| ES2606511T3 (es) | 2011-04-06 | 2017-03-24 | Biovaxim Limited | Composiciones farmacéuticas para prevenir y/o tratar una enfermedad por VIH en seres humanos |
| WO2014018850A2 (en) * | 2012-07-27 | 2014-01-30 | The Trustees Of The University Of Pennsylvania | Cytoplasmic tail modifications to boost surface expression and immunogenicity of envelope glycoproteins |
| WO2016068919A1 (en) | 2014-10-29 | 2016-05-06 | Geovax, Inc. | Combination therapy for treating viral reservoirs |
| EP3244919A4 (en) | 2015-01-12 | 2018-06-27 | Geovax, Inc. | Compositions and methods for generating an immune response to a hemorrhagic fever virus |
| PL3402802T3 (pl) | 2016-01-08 | 2023-06-05 | Geovax, Inc. | Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym |
| WO2017136419A1 (en) | 2016-02-03 | 2017-08-10 | Geovax Inc. | Compositions and methods for generating an immune response to a flavivirus |
| AU2017221379A1 (en) | 2016-02-16 | 2018-08-16 | Geovax Inc. | Multivalent HIV vaccine boost compositions and methods of use |
| WO2018195447A1 (en) * | 2017-04-20 | 2018-10-25 | Geovax Labs, Inc. | Recombinant mva-based hiv immunogens and uses thereof |
| WO2019018501A1 (en) * | 2017-07-18 | 2019-01-24 | Geovax Inc. | COMPOSITIONS AND METHODS FOR GENERATING LASV IMMUNE RESPONSE |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0243029A1 (en) * | 1986-04-08 | 1987-10-28 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Recombinant vaccinia virus expressing human retrovirus gene |
| US5169763A (en) * | 1986-04-08 | 1992-12-08 | Transgene S.A., Institut Pasteur | Viral vector coding glycoprotein of HIV-1 |
| US5256767A (en) * | 1987-06-10 | 1993-10-26 | The Immune Response Corporation | Retroviral antigens |
| CA1341245C (en) * | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| CA1340729C (en) | 1988-03-23 | 1999-09-07 | Mohan Bir Singh | Ryegrass pollen allergen |
| IL89567A0 (en) | 1988-03-28 | 1989-09-10 | Univ Leland Stanford Junior | Mutated hiv envelope protein |
| US5747324A (en) * | 1988-06-10 | 1998-05-05 | Therion Biologics Corporation | Self-assembled, defective, non-self-propagating lentivirus particles |
| US5614404A (en) * | 1988-06-10 | 1997-03-25 | Theriod Biologics, Incorporated | Self-assembled, defective, non-self-propagating lentivirus particles |
| WO1989012095A1 (en) * | 1988-06-10 | 1989-12-14 | Applied Biotechnology, Inc. | A method of evaluating recombinant vaccines against immunodeficiency virus |
| US6306625B1 (en) * | 1988-12-30 | 2001-10-23 | Smithkline Beecham Biologicals, Sa | Method for obtaining expression of mixed polypeptide particles in yeast |
| US6214804B1 (en) * | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| GB8923123D0 (en) * | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| JPH05503629A (ja) * | 1989-11-20 | 1993-06-17 | オンコーゲン リミテッド パートナーシップ | 抗ウィルス剤及び免疫原として使用される、非複製組換え製レトロウィルス粒子 |
| IE68404B1 (en) * | 1990-11-20 | 1996-06-12 | Virogenetics Corp | Measles virus recombinant poxvirus vaccine |
| AU672359B2 (en) * | 1991-03-07 | 1996-10-03 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5863542A (en) * | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
| DE69133333T2 (de) * | 1991-08-26 | 2004-07-29 | Baxter Healthcare S.A. | Ein intaktes FPV-tk-Gen enthaltender rekombinanter Virus der Vogelpocken |
| US5445953A (en) * | 1991-08-26 | 1995-08-29 | Immuno Aktiengesellschaft | Direct molecular cloning of a modified poxvirus genome |
| ATE181108T1 (de) * | 1991-08-26 | 1999-06-15 | Immuno Ag | Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus |
| US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US6171596B1 (en) * | 1993-12-10 | 2001-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Oligomeric HIV-1 envelope glycoproteins |
| US5658785A (en) * | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5955342A (en) * | 1994-08-15 | 1999-09-21 | Connaught Laboratories Limited | Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region |
| US6291157B1 (en) * | 1998-02-23 | 2001-09-18 | Connaught Laboratories Limited | Antigenically-marked non-infectious retrovirus-like particles |
| US6080408A (en) | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
| US5676950A (en) * | 1994-10-28 | 1997-10-14 | University Of Florida | Enterically administered recombinant poxvirus vaccines |
| AU2308595A (en) * | 1995-04-19 | 1996-11-07 | Polymun Scientific Immunobiologische Forschung Gmbh | Monoclonal antibodies against hiv-1 and vaccines made thereo f |
| US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
| FR2747046B1 (fr) * | 1996-04-05 | 1998-06-19 | Univ Paris Curie | Nouveaux vaccins issus de plasmovirus |
| US5846946A (en) * | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
| US5747338A (en) * | 1996-08-15 | 1998-05-05 | Chiron Corporation | Method and construct for screening for inhibitors of transcriptional activation |
| US6201663B1 (en) * | 1996-09-05 | 2001-03-13 | Kabushiki Kaisha Ohara | Magnetic head having a slider made of a glass-ceramic |
| US6204250B1 (en) * | 1996-11-22 | 2001-03-20 | The Mount Sinai Medical Center Of The City Of New York | Immunization of infants |
| US6077662A (en) * | 1996-11-27 | 2000-06-20 | Emory University | Virus-like particles, methods and immunogenic compositions |
| US6099847A (en) * | 1997-05-15 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric Gag pseudovirions |
| GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| US6054312A (en) * | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
| US6121021A (en) * | 1997-12-16 | 2000-09-19 | Connaught Laboratories Limited | Constitutive expression of non-infectious HIV-like particles |
| US6156952A (en) * | 1998-04-09 | 2000-12-05 | Constituent Institution Of The University Of Maryland System | HIV transgenic animals and uses therefor |
| AUPP349698A0 (en) * | 1998-05-13 | 1998-06-04 | Altronic Distributors Pty Ltd | Mounting assembly |
| GB2337755B (en) * | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
| WO2000000216A2 (en) | 1998-06-26 | 2000-01-06 | Aventis Pasteur | Use of poxviruses as enhancer of specific immunity |
| US6210663B1 (en) | 1998-08-20 | 2001-04-03 | The Wistar Institute Of Anatomy And Biology | Methods of augmenting mucosal immunity through systemic priming and mucosal boosting |
| EP1200622A4 (en) | 1999-07-06 | 2004-12-22 | Merck & Co Inc | HIV VACCINE FROM AN ADENOVIRUS CARRYING THE GAG GENE |
| US6256183B1 (en) * | 1999-09-09 | 2001-07-03 | Ferraz Shawmut Inc. | Time delay fuse with mechanical overload device and indicator actuator |
| WO2001047955A2 (en) * | 1999-12-23 | 2001-07-05 | Medical Research Council | Improvements in or relating to immune responses to hiv |
| AUPQ520800A0 (en) | 2000-01-21 | 2000-02-17 | Alfred Hospital | Prime-boost vaccination strategy |
| CN1311871C (zh) * | 2000-03-02 | 2007-04-25 | 爱莫里大学 | Dna表达载体及其应用方法 |
| DK1280551T3 (da) | 2000-04-27 | 2007-05-21 | Sanofi Pasteur Ltd | Vacciner mod HIV-infektion |
| AU2002252199B2 (en) | 2001-03-08 | 2008-01-03 | Emory University | MVA expressing modified HIV envelope, GAG, and POL genes |
| JP4302513B2 (ja) | 2001-07-05 | 2009-07-29 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 抗原性ｂ型ｈｉｖポリペプチドおよび／または抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用 |
-
2002
- 2002-03-01 AU AU2002252199A patent/AU2002252199B2/en not_active Ceased
- 2002-03-01 ES ES02721259T patent/ES2334335T3/es not_active Expired - Lifetime
- 2002-03-01 PT PT02721259T patent/PT1372710E/pt unknown
- 2002-03-01 DE DE60234018T patent/DE60234018D1/de not_active Expired - Lifetime
- 2002-03-01 DK DK02721259.6T patent/DK1372710T3/da active
- 2002-03-01 EP EP02721259A patent/EP1372710B1/en not_active Expired - Lifetime
- 2002-03-01 AT AT02721259T patent/ATE445411T1/de active
- 2002-03-01 CN CNB028095383A patent/CN100446812C/zh not_active Expired - Fee Related
- 2002-03-01 CA CA2454959A patent/CA2454959C/en not_active Expired - Lifetime
- 2002-03-01 WO PCT/US2002/006713 patent/WO2002072754A2/en not_active Ceased
- 2002-03-01 JP JP2002571810A patent/JP4554887B2/ja not_active Expired - Lifetime
-
2003
- 2003-08-22 US US10/646,628 patent/US20040146528A1/en not_active Abandoned
-
2008
- 2008-01-22 US US12/018,150 patent/US7867982B2/en not_active Expired - Fee Related
-
2009
- 2009-12-23 CY CY20091101339T patent/CY1109659T1/el unknown
-
2010
- 2010-01-29 JP JP2010019755A patent/JP2010115208A/ja not_active Ceased
-
2011
- 2011-01-10 US US12/987,791 patent/US8916172B2/en not_active Expired - Fee Related
-
2014
- 2014-12-10 US US14/566,066 patent/US20150238593A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004537974A5 (enExample) | ||
| Robinson | New hope for an AIDS vaccine | |
| Otten et al. | Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins | |
| US20110142880A1 (en) | Lentivirus-based immunogenic vectors | |
| US8916174B2 (en) | HIV DNA vaccine regulated by a caev-derived promoter | |
| Stratov et al. | Vaccines and vaccine strategies against HIV | |
| Schultz et al. | The HIV vaccine pipeline, from preclinical to phase III | |
| US8685407B2 (en) | Genetic constructs and compositions comprising RRE and CTE and uses thereof | |
| AU2005243730B2 (en) | Method of using adenoviral vectors to induce an immune response | |
| US8765140B2 (en) | DNA vaccine compositions with HIV/SIV gene modifications | |
| Fultz et al. | Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6 P disease | |
| CN101394868A (zh) | 重组腺病毒5型/35型和痘病毒mva活病毒载体疫苗的联用诱导强大的免疫应答的方法 | |
| Moriya et al. | Abrogation of AIDS vaccine-induced cytotoxic T-lymphocyte efficacy in vivo due to a change in viral epitope flanking sequences | |
| McGettigan et al. | HIV-1 vaccines: the search continues | |
| JP2017512499A (ja) | モザイクｈｉｖ−１配列およびその使用 | |
| Jesil et al. | HIV VACCI ES: PRESE T SCE ARIO AD FUTURE PROSPECTS | |
| JP2024509976A (ja) | 抗原をｍｈｃ－ｉｉ経路にターゲティングし、宿主におけるｃｄ８＋及びｃｄ４＋ｔ細胞による防御免疫を誘導するレンチウイルスベクター | |
| Womack et al. | Challenges and current stratiges in the development of HIV/AIDS vaccines | |
| Smith | Design and immunogenicity of a DNA vaccine against primate lentiviruses | |
| Hallengärd | Strategies to enhance the potency of HIV-1 DNA vaccines | |
| Rosenwirth et al. | A vaccine strategy utilizing a combination of | |
| Seth | HIV-1 subtype C vaccine: waiting in wings for the human trials | |
| Seth et al. | Development of Indian HIV-1 Subtype C Vaccine Candidates | |
| Cavicchi et al. | Franklin Pierce Law Center Educational Report: Patent Landscape of DNA Vaccines for HIV |